A 56‐year‐old male with a diagnosis of relapsed mantle cell lymphoma was recruited to a clinical trial to receive CD19 chimeric antigen receptor (CAR) T‐cell therapy (ALLCAR19 trial, NCT02935257). Here, CD19 is linked to mantle cell lymphoma.